TCR2 Therapeutics Inc. announced it has entered into a Cooperative Research and Development Agreement with NCI to collaborate on the use of TCR2’s proprietary T cell receptor Fusion Construct T cells as a cancer therapeutic agent against mesothelin in the Company’s ongoing phase I/II trial of TC-210.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
